Mark Street-Docherty
Chief Executive Officer at Rosa Biotech Ltd.
Profile
Mark Street-Docherty is currently the Chief Executive Officer at Rosa Biotech Ltd.
He previously held the position of Chief Executive Officer at Delta Diagnostics (UK) Ltd.
from 2017 to 2020.
Mark Street-Docherty active positions
| Companies | Position | Start |
|---|---|---|
Rosa Biotech Ltd.
 Rosa Biotech Ltd. Packaged SoftwareTechnology Services Rosa Biotech Ltd. is a British company that is redefining biosensing. The company is based in Bristol, UK. The company is focused on addressing intractable challenges in early disease diagnosis and industrial biotechnology. The company was founded in 2019. Mark Street-Docherty has been the CEO of the company since 2022. | Chief Executive Officer | 2022-05-31 |
Former positions of Mark Street-Docherty
| Companies | Position | End |
|---|---|---|
Delta Diagnostics (UK) Ltd.
 Delta Diagnostics (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Delta Diagnostics Ltd. develops and provides assays diagnostics solutions. It offers cystic fibrosis, rapid aneuploidy analysis, and genetic disease diagnosis. The company was founded in 1994 and is headquartered in Lancashire, the United Kingdom. | Chief Executive Officer | 2019-12-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Delta Diagnostics (UK) Ltd.
Delta Diagnostics (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Delta Diagnostics Ltd. develops and provides assays diagnostics solutions. It offers cystic fibrosis, rapid aneuploidy analysis, and genetic disease diagnosis. The company was founded in 1994 and is headquartered in Lancashire, the United Kingdom. | Commercial Services |
Rosa Biotech Ltd.
Rosa Biotech Ltd. Packaged SoftwareTechnology Services Rosa Biotech Ltd. is a British company that is redefining biosensing. The company is based in Bristol, UK. The company is focused on addressing intractable challenges in early disease diagnosis and industrial biotechnology. The company was founded in 2019. Mark Street-Docherty has been the CEO of the company since 2022. | Technology Services |
- Stock Market
- Insiders
- Mark Street-Docherty
